| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.2 - Asthma, Diagnosed | 2013 | Korea, Republic of | IgE | 8 | 12.500 | 20131122, Nam YH
| | 1.3 - Rhinitis, Diagnosed | 2013 | Brazil | IgE | 101 | 0.000 | 20130912, Lacerda Araujo LM
| | 1.6 - Anaphylaxis, Diagnosed | 2013 | Japan | IgE | 36 | 50.000 | 20130424, Kohno K
| | 1.6 - Anaphylaxis, Diagnosed | 2013 | Korea, Republic of | IgE | 20 | 70.000 | 20131122, Nam YH
| | 6.5 - Occupational Exposure | 2013 | Italy | IgE | 51 | 0.000 | 20130520, Olivieri M
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 0.000 | 20120528, Patelis A
| | 1.9 - Pollen Allergy | 2012 | France | IgE | 10 | 3.000 | 20121030, Mameri H
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 0.000 | 20110223, De Knop KJ
| | 10.1 - Normal Control | 2012 | France | IgE | 12 | 16.660 | 20121030, Mameri H
| | 5.2.4 - Source Exposed, Adults (Symptoms, IgE) | 2012 | France | IgE | 21 | 52.380 | 20121030, Mameri H
| | 5.2.5 - Source Exposed, Children (Symptoms, IgE) | 2012 | France | IgE | 82 | 79.270 | 20121030, Mameri H
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 3.030 | 20110223, De Knop KJ
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Japan | IgE | 54 | 37.000 | 20121024, Chinuki Y
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Japan | IgE | 30 | 76.600 | 20121024, Chinuki Y
| | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 0.000 | 20120528, Patelis A
| | 6.5 - Occupational Exposure | 2012 | France | IgE | 29 | 65.510 | 20121030, Mameri H
| | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 2011 | China | IgE | 100 | 0.000 | 20111214, Zheng YW
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Belgium | IgE | 86 | 9.302 | 20101214, Gadisseur R
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Italy | IgE | 16408 | 0.270 | 20100301, Scala E
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2010 | Japan | IgE | 23 | 78.260 | 20101124, Fukutomi Y
| | 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 4.550 | 20091121, Ebo DG
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 0.000 | 20091121, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 0.000 | 20090826, Ebo DG
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2009 | France | IgE | 24 | 70.830 | 20081126, Jacquenet S
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2009 | Spain | SPT | 8 | 12.500 | 20091217, Palacin A
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2008 | Japan | IgE | 50 | 56.000 | 20080104, Matsuo H
| | 6.5 - Occupational Exposure | 2007 | Germany | IgE | 153 | 32.680 | 20071126, Bittner C
| | 6.3 - General Population (Children) | 2005 | Italy | IgE | 263 | 3.000 | 20060203, Caruso B
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2003 | France | IgE | 27 | 66.600 | 20030720, Battais F
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2000 | Finland | IgE | 13 | 100.000 | 2000, Varjonen E
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2000 | Finland | SPT | 13 | 92.300 | 2000, Varjonen E
|
|
Loading...
Tri a Gliadin
